Personal information

Other IDs

Scopus Author ID: 7003908941
Loop profile: 1028232

Countries

France

Activities

Collapse all

Employment (3)

Institut Universitaire de Cancérologie AP-HP Sorbonne Université: Paris, Île-de-France, FR

2018-11-01 to present | Executive Director (Governance)
Employment
Source: Self-asserted source
Joseph Gligorov

INSERM U938: Paris, FR

2014-01-01 to present (Cancer Biology and Treatment)
Employment
Source: Self-asserted source
Joseph Gligorov

Assistance Publique - Hôpitaux de Paris: Paris, Île-de-France, FR

1998-11-01 to present | Head of Breast Cancer Expert Center (Medical Oncology)
Employment
Source: Self-asserted source
Joseph Gligorov

Professional activities (5)

European Society for Medical Oncology: Lugano, Ticino, CH

Service
Source: Self-asserted source
Joseph Gligorov

American Society of Clinical Oncology: Alexandria, VA, US

Service
Source: Self-asserted source
Joseph Gligorov

Saints Cyril and Methodius University in Skopje Medical Faculty: Skopje, Skopje, MK

2018 to present | Associate Professor (Oncology)
Invited position
Source: Self-asserted source
Joseph Gligorov

University of Belgrade Medical Faculty: Belgrade, Belgrade, RS

2016 to present | Associate Professor (Oncology)
Invited position
Source: Self-asserted source
Joseph Gligorov

Macedonian Academy of Sciences and Arts: Skopje, Skopje, MK

2022-03 | Member (Medical Sciences)
Distinction
Source: Self-asserted source
Joseph Gligorov

Works (50 of 227)

Items per page:
Page 1 of 5

Can a physical activity program improve functional capacity and fatigue in people with cancer? A retrospective analysis

BMC Sports Science, Medicine and Rehabilitation
2025-02-06 | Journal article
DOI: 10.1186/s13102-025-01066-w
Contributors: Aline Reinmann; Edouard Laré; Anne-Violette Bruyneel; Joseph Gligorov; Alexandre Bodmer; Thibaud Koessler
Source: check_circle
Crossref

Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence

Cancers
2023-04-13 | Journal article
DOI: 10.3390/cancers15082278
Contributors: Kamel Debbi; Noémie Grellier; Gokoulakrichenane Loganadane; Chahrazed Boukhobza; Mathilde Mahé; Mohamed Aziz Cherif; Hanan Rida; Joseph Gligorov; Yazid Belkacemi
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Systemic therapy for early-stage breast cancer: learning from the past to build the future

Nature Reviews Clinical Oncology
2022-12 | Journal article
DOI: 10.1038/s41571-022-00687-1
Contributors: Elisa Agostinetto; Joseph Gligorov; Martine Piccart
Source: check_circle
Crossref

Influence of chemotherapy on postural control and quality of life in women with gynaecological cancer: a protocol of a prospective observational study

BMJ Open
2022-09 | Journal article
DOI: 10.1136/bmjopen-2022-061664
Contributors: Aline Reinmann; Anne-Violette Bruyneel; Joseph Gligorov; Serge Mesure; Christophe Combescure; Thibaud Koessler; Alexandre Bodmer
Source: check_circle
Crossref

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study

The Breast
2022-08 | Journal article
DOI: 10.1016/j.breast.2022.03.001
Contributors: Joseph Gligorov; Xavier Pivot; Beyhan Ataseven; Michelino De Laurentiis; Kyung Hae Jung; Alexey Manikhas; Hamdy Abdel Azim; Kushagra Gupta; Ari Alexandrou; Luis Herraez-Baranda et al.
Source: check_circle
Crossref

Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study

Cancers
2021-09 | Journal article | Author
DOI: 10.3390/cancers13194749
Contributors: Marc-Antoine BENDERRA; Ainhoa Aparicio; Judith LEBLANC; Thomas Moreau; Demian Wassermann; Emmanuelle Kempf; Gilles Galula; Mélodie Bernaux; Anthony Canellas; Ali Bellamine et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe

The Breast
2021-02 | Journal article
DOI: 10.1016/j.breast.2020.12.005
Contributors: Eduard Vrdoljak; Joseph Gligorov; Lieve Wierinck; PierFranco Conte; Jacques De Grève; Françoise Meunier; Carlo Palmieri; Luzia Travado; Andrew Walker; Theresa Wiseman et al.
Source: check_circle
Crossref

Prognosis of HER2-positive pregnancy-associated breast cancer: Analysis from the French CALG (Cancer Associé à La Grossesse) network

The Breast
2020-12 | Journal article
DOI: 10.1016/j.breast.2020.11.013
Contributors: Anne-Sophie Boudy; Clément Ferrier; Lise Selleret; Sonia Zilberman; Alexandra Arfi; Julie Sussfeld; Joseph Gligorov; Sandrine Richard; Sofiane Bendifallah; Nathalie Chabbert-Buffet et al.
Source: check_circle
Crossref

Centre expert Cancer du sein et Grossesse (CALG) : concordance entre la proposition du CALG et la prise en charge effective

Gynécologie Obstétrique Fertilité & Sénologie 
2019-01 | Journal article
DOI: 10.1016/j.gofs.2018.10.001
Contributors: J. De Garnier; A.S. Boudy; L. Selleret; J. Gligorov; N. Chabbert-Buffet; S. Bendifallah; E. Darai
Source: check_circle
Crossref

High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)

Clinical Cancer Research
2018-07-01 | Journal article
DOI: 10.1158/1078-0432.CCR-17-1864
Contributors: Saranya Chumsri; Jeff Sperinde; Heshan Liu; Joseph Gligorov; Jean-Philippe Spano; Martine Antoine; Alvaro Moreno Aspitia; Winston Tan; John Winslow; Christos J. Petropoulos et al.
Source: check_circle
Crossref

The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer

Clinical Breast Cancer
2018-04 | Journal article
DOI: 10.1016/j.clbc.2018.01.006
Contributors: Kimberly Blackwell; Joseph Gligorov; Ira Jacobs; Chris Twelves
Source: check_circle
Crossref

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

European Journal of Cancer
2017-09 | Journal article
DOI: 10.1016/j.ejca.2017.05.010
Contributors: J. Gligorov; B. Ataseven; M. Verrill; M. De Laurentiis; K.H. Jung; H.A. Azim; N. Al-Sakaff; S. Lauer; M. Shing; X. Pivot et al.
Source: check_circle
Crossref

Intensive chemotherapy as salvage treatment for solid tumors: Focus on germ cell cancer

2015 | Journal article
DOI:

10.1590/1414-431X20144214

EID:

2-s2.0-84916910393
Contributors: Selle, F.; Gligorov, J.; Richard, S.; Khalil, A.; Alexandre, I.; Avenin, D.; Provent, S.; Soares, D.G.; Lotz, J.P.
Source: Self-asserted source
Joseph Gligorov via Scopus - Elsevier

Looking for predictive markers in breast cancer - Authors' reply.

2015-01 | Journal article
DOI:

10.1016/S1470-2045(14)71175-1

PMID:

25638543
Contributors: Gligorov J
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central

Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer: Overall survival and subgroup analyses of the ATHENA study in France | Bévacizumab et taxanes dans le traitement de première ligne du cancer du sein métastatique: Survie globale et analyse de sous-groupes de l'étude ATHENA France

2014 | Journal article
EID:

2-s2.0-84908691593
Contributors: Pierga, J.-Y.; Delva, R.; Pivot, X.; Espié, M.; Dalenc, F.; Serin, D.; Veyret, C.; Lortholary, A.; Gligorov, J.; Joly, K. et al.
Source: Self-asserted source
Joseph Gligorov via Scopus - Elsevier

Chemotherapy for high-risk gestational trophoblastic tumors | Chimiothérapie des tumeurs trophoblastiques gestationnelles à haut risque

2014 | Journal article
DOI:

10.1007/s10269-014-2402-2

EID:

2-s2.0-84903736764
Contributors: Richard, S.; Baste-Rotllan, N.; Soares, D.G.; Selle, F.; Khalil, A.; Gligorov, J.; Avenin, D.; Provent, S.; Lotz, J.-P.
Source: Self-asserted source
Joseph Gligorov via Scopus - Elsevier

First collaboration between Oncologie and FFCD ! | Une première collaboration entre Oncologie et la Fédération Française de Cancérologie Digestive (FFCD) !

2014 | Journal article
DOI:

10.1007/s10269-014-2476-x

EID:

2-s2.0-84920065174
Contributors: Culine, S.; Gligorov, J.; Krakowski, I.; Marti, P.; Metges, J.-P.; Serin, D.; Schneider, M.; Spielmann, M.
Source: Self-asserted source
Joseph Gligorov via Scopus - Elsevier

Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.

2014 | Journal article
DOI:

10.1186/1471-2407-14-991

PMID:

25535397
Contributors: Chaari M; Ayadi I; Rousseau A; Lefkou E; Van Dreden P; Sidibe F; Ketatni H; Galea V; Khaterchi A; Bouzguenda R et al.
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central

The privilege of a specialty that moves | Le privilège d'une spécialité en mouvement

2014 | Journal article
DOI:

10.1007/s10269-014-2441-8

EID:

2-s2.0-84905316980
Contributors: Gligorov, J.; Culine, S.; Krakowski, I.; Marti, P.; Metges, J.-P.; Serin, D.; Schneider, M.; Spielmann, M.
Source: Self-asserted source
Joseph Gligorov via Scopus - Elsevier

Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.

2014-12 | Journal article
DOI:

10.1158/1078-0432.CCR-14-1705

PMID:

25538259
Contributors: Pierga J; Petit T; Levy C; Ferrero JM; Campone M; Gligorov J; Lerebours F; Roche H; Bachelot T; Charafe-Jauffret EA et al.
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central

Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer.

2014-11 | Journal article
PMID:

25372715
Contributors: Selle F; Gligorov J; Richard S; Khalil A; Alexandre I; Avenin D; Provent S; Soares DG; Lotz JP
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 3)‎

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.

2014-11 | Journal article
DOI:

10.1016/S1470-2045(14)70444-9

PMID:

25273343
Contributors: Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S et al.
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

[Use of guidelines and heterogeneity of decision making for adjuvant chemotherapy in hormone-receptor positive, HER2-negative, early breast cancer: results of a French national survey].

2014-10 | Journal article
DOI:

10.1684/bdc.2014.2030

PMID:

25373691
Contributors: Fekih M; Petit T; Zarca D; Guinebretière JM; André F; Pierga JY; Namer M; Gligorov J; Delaloge S
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.

2014-10 | Journal article
DOI:

10.1016/S1470-2045(14)70439-5

PMID:

25273342
Contributors: von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E et al.
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

2014-10 | Journal article
DOI:

10.1016/j.breast.2014.08.009

PMID:

25244983
Contributors: Cardoso F; Costa A; Norton L; Senkus E; Aapro M; André F; Barrios CH; Bergh J; Biganzoli L; Blackwell KL et al.
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.

2014-10 | Journal article
DOI:

10.1093/annonc/mdu385

PMID:

25234545

PMC:

PMC4176456
Contributors: Cardoso F; Costa A; Norton L; Senkus E; Aapro M; André F; Barrios CH; Bergh J; Biganzoli L; Blackwell KL et al.
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.

2014-10 | Journal article
DOI:

10.1093/annonc/mdu364

PMID:

25070545
Contributors: Pivot X; Gligorov J; Müller V; Curigliano G; Knoop A; Verma S; Jenkins V; Scotto N; Osborne S; Fallowfield L et al.
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central

[Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France].

2014-09 | Journal article
DOI:

10.1684/bdc.2014.2019

PMID:

25295737
Contributors: Pierga JY; Delva R; Pivot X; Espié M; Dalenc F; Serin D; Veyret C; Lortholary A; Gligorov J; Joly K et al.
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central

[Delays in treatment of breast cancer: experience of an expert center of the Assistance Publique-Hopitaux de Paris (AP-HP)].

2014-09 | Journal article
DOI:

10.1016/j.gyobfe.2014.05.005

PMID:

24993654
Contributors: Revaux A; Laas E; Chopier J; Thomassin-Naggara I; Touboul E; Antoine M; Gligorov J; Darai E
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.

2014-09 | Journal article
DOI:

10.1093/annonc/mdu198

PMID:

24894084
Contributors: Selle F; Wittnebel S; Biron P; Gravis G; Roubaud G; Bui BN; Delva R; Bay JO; Fléchon A; Geoffrois L et al.
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.

2014-08 | Journal article
DOI:

10.1093/annonc/mdu183

PMID:

24827135
Contributors: Nabholtz JM; Abrial C; Mouret-Reynier MA; Dauplat MM; Weber B; Gligorov J; Forest AM; Tredan O; Vanlemmens L; Petit T et al.
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

Just ten years: The 5th French-speaking Guidelines of Saint-Paul-de-Vence | Juste dix ans: 5es Recommandations francophones de Saint-Paul-de-Vence

2013 | Journal article
DOI:

10.1007/s10269-013-2358-7

EID:

2-s2.0-84893410842
Contributors: Gligorov, J.; Namer, M.
Source: Self-asserted source
Joseph Gligorov via Scopus - Elsevier

Modification of tumoral metabolism during treatment: Assessing tumor response with positron emission tomography | Modification du métabolisme tumoral au cours du traitement: suivi de la réponse thérapeutique par tomographie par émission de positons

2013 | Journal article
DOI:

10.1007/s10269-013-2322-6

EID:

2-s2.0-84885678216
Contributors: Gillebert, Q.; Gligorov, J.; Kerrou, K.
Source: Self-asserted source
Joseph Gligorov via Scopus - Elsevier

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.

2013-10 | Journal article
DOI:

10.1007/s10549-013-2689-5

PMID:

24101324

PMC:

PMC3824346
Contributors: Hurvitz SA; Dalenc F; Campone M; O'Regan RM; Tjan-Heijnen VC; Gligorov J; Llombart A; Jhangiani H; Mirshahidi HR; Tan-Chiu E et al.
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: a review.

2013-10 | Journal article
DOI:

10.1016/j.critrevonc.2013.03.003

PMID:

23566949
Contributors: Thibault C; Khodari W; Lequoy M; Gligorov J; Belkacémi Y
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.

2013-09 | Journal article
DOI:

10.1016/S1470-2045(13)70383-8

PMID:

23965225
Contributors: Pivot X; Gligorov J; Müller V; Barrett-Lee P; Verma S; Knoop A; Curigliano G; Semiglazov V; López-Vivanco G; Jenkins V et al.
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

Which breast cancer decisions remain non-compliant with guidelines despite the use of computerised decision support?

2013-09 | Journal article
DOI:

10.1038/bjc.2013.453

PMID:

23942076

PMC:

PMC3778303
Contributors: Séroussi B; Laouénan C; Gligorov J; Uzan S; Mentré F; Bouaud J
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

Acute kidney failure with renal carcinomatous lymphangitis secondary to advanced colon cancer.

2013-08 | Journal article
DOI:

10.1038/ki.2012.480

PMID:

23903432
Contributors: Robert T; Moktefi A; Wiig H; Brochériou I; Michaud L; Gligorov J; Finianos S; Hertig A
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

2013-07 | Journal article
DOI:

10.1016/S1470-2045(13)70225-0

PMID:

23764181
Contributors: Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D et al.
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central

Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients.

2013-06 | Journal article
DOI:

10.1007/s10549-013-2545-7

PMID:

23666532
Contributors: Lévy P; Gligorov J; Antoine M; Rezai K; Lévy E; Selle F; Saintigny P; Lokiec F; Avenin D; Beerblock K et al.
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer.

2013-06 | Journal article
DOI:

10.1016/j.breast.2013.03.006

PMID:

23601761
Contributors: Lin NU; Thomssen C; Cardoso F; Cameron D; Cufer T; Fallowfield L; Francis PA; Kyriakides S; Pagani O; Senkus E et al.
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central

[Impact of taxanes in the adjuvant setting of node-negative breast cancers].

2013-05 | Journal article
DOI:

10.1684/bdc.2013.1743

PMID:

23613145
Contributors: Lagha A; Chraiet N; Labidi S; Krimi S; Ayadi M; Gligorov J; Boussen H
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

[Are decisions of multidisciplinary tumor boards in accordance with the guidelines? Experience of an university reference center for breast cancer].

2013-03 | Journal article
DOI:

10.1016/j.gyobfe.2013.01.003

PMID:

23481026
Contributors: Touboul C; Bezu C; Daraï E; Chopier J; Touboul E; Gligorov J; Rouzier R; Uzan S
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France.

2012 | Journal article
DOI:

10.3111/13696998.2012.713414

PMID:

22853442
Contributors: Laas E; Vataire AL; Aballea S; Valentine W; Gligorov J; Chereau E; Rouzier R
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

Impact of immunohistochemical analysis of sentinel lymph node biopsy on breast cancer management

2012 | Journal article
EID:

2-s2.0-84865682659
Contributors: Chéreau, E.; Bezu, C.; Gligorov, J.; Sakr, R.; Antoine, M.; Daraï, E.; Uzan, S.; Rouzier, R.
Source: Self-asserted source
Joseph Gligorov via Scopus - Elsevier

Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.

2012 | Journal article
DOI:

10.1634/theoncologist.2011-0344

PMID:

22467666

PMC:

PMC3336828
Contributors: Martín M; Makhson A; Gligorov J; Lichinitser M; Lluch A; Semiglazov V; Scotto N; Mitchell L; Tjulandin S
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

Fight against cancer around the Mediterranean area: "Many hands make light work!".

2012-12 | Journal article
DOI:

10.1016/j.critrevonc.2012.10.004

PMID:

23177098
Contributors: Belkacémi Y; Boussen H; Turkan S; Tsoutsou PG; Geara F; Gligorov J
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

[Cost-effectiveness of a chemotherapy predictive test].

2012-10 | Journal article
DOI:

10.1684/bdc.2012.1652

PMID:

23041366
Contributors: Vataire AL; Laas E; Aballéa S; Gligorov J; Rouzier R; Chéreau E
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

Adjuvant treatments for triple-negative breast cancers.

2012-08 | Journal article
DOI:

10.1093/annonc/mds194

PMID:

23012301
Contributors: Joensuu H; Gligorov J
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
grade
Preferred source (of 2)‎

Impact of immunohistochemical analysis of sentinel lymph node biopsy on breast cancer management.

2012-08 | Journal article
PMID:

22843922
Contributors: Chéreau E; Bezu C; Gligorov J; Sakr R; Antoine M; Daraï E; Uzan S; Rouzier R
Source: Self-asserted source
Joseph Gligorov via Europe PubMed Central
Items per page:
Page 1 of 5

Peer review (3 reviews for 3 publications/grants)

Review activity for Bulletin du cancer. (1)
Review activity for European journal of cancer. (1)
Review activity for The Breast. (1)
How many people are using ORCID?